10,000 Shares in CME Group Inc. $CME Purchased by BlueCrest Capital Management Ltd

Key Points

• BlueCrest Capital Management acquired 10,000 CME Group shares worth approximately $2.2 million, while institutional investors collectively own 87.75% of the company.
• CME Group beat quarterly earnings and revenue expectations, reporting $2.99 in EPS and $1.71 billion in revenue. The company also declared a $1.30 quarterly dividend, equivalent to $5.20 annually and a 1.9% yield.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $289.75 versus the stock’s reported price of $274.70.

BlueCrest Capital Management Ltd acquired a new position in shares of CME Group Inc. (NASDAQ:CME - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,000 shares of the financial services provider's stock, valued at approximately $2,208,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC raised its position in CME Group by 2,075.0% in the 1st quarter. Whipplewood Advisors LLC now owns 87 shares of the financial services provider's stock worth $26,000 after purchasing an additional 83 shares during the last quarter. Elkhorn Partners Limited Partnership bought a new position in CME Group in the 4th quarter valued at $27,000. Hilton Head Capital Partners LLC bought a new position in CME Group in the 4th quarter valued at $28,000. Main Street Group LTD acquired a new stake in shares of CME Group in the 1st quarter valued at $32,000. Finally, Bayban acquired a new stake in shares of CME Group in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 87.75% of the company's stock.

CME Group Price Performance

CME Group stock opened at $274.70 on Thursday. The firm has a market capitalization of $98.78 billion, a P/E ratio of 23.30, a PEG ratio of 3.29 and a beta of 0.24. CME Group Inc. has a 1 year low of $218.31 and a 1 year high of $329.16. The business has a 50-day moving average of $262.03 and a 200-day moving average of $277.67. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13.

CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The financial services provider reported $2.99 EPS for the quarter, beating analysts' consensus estimates of $2.91 by $0.08. CME Group had a return on equity of 15.60% and a net margin of 63.30%.The company had revenue of $1.71 billion during the quarter, compared to analysts' expectations of $1.68 billion. During the same period in the prior year, the business posted $2.96 EPS. CME Group's revenue was up .8% on a year-over-year basis. On average, equities analysts anticipate that CME Group Inc. will post 12.27 EPS for the current year.

CME Group Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Wednesday, September 9th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Wednesday, September 9th. CME Group's dividend payout ratio is presently 44.11%.

Insiders Place Their Bets

In other news, Director William Shepard bought 325 shares of the business's stock in a transaction on Thursday, June 25th. The shares were bought at an average cost of $230.57 per share, for a total transaction of $74,935.25. Following the completion of the acquisition, the director owned 260,442 shares in the company, valued at approximately $60,050,111.94. This trade represents a 0.12% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.30% of the company's stock.

CME Group News Summary

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Shareholder distribution: CME is scheduled to distribute approximately $467 million in dividends on September 25, reinforcing its appeal to income-oriented investors and highlighting the exchange operator’s strong cash-generation profile. CME Group's $467 Million Dividend: What Shareholders Collect Sept. 25
• Positive Sentiment: Product expansion: CME’s new single-stock futures offer investors leveraged and capital-efficient exposure to individual equities. The product broadens CME’s equity derivatives lineup and could create additional trading volume and fee revenue over time. CME's New Single Stock Futures: What Are The Advantages Vs. Stocks?
• Positive Sentiment: European market entry: CME plans to enter the European dairy market through a deal involving EEX, expanding its addressable market and potentially improving its international commodities presence. CME Group to enter European dairy market through EEX deal
• Neutral Sentiment: Leadership succession: CME named insider Jack Tobin as CFO, succeeding Lynne Fitzpatrick, who is expected to become CEO in March 2027. The planned internal transition may provide continuity, although investors could monitor execution during the leadership change. CME Group names Jack Tobin as CFO
• Neutral Sentiment: Interest-rate backdrop: Reports that Federal Reserve Chair Warsh favors rate hikes, while the Treasury considers buying longer-maturity debt, point to continued uncertainty over rates, inflation and bond-market conditions. These factors can affect CME’s interest-rate and fixed-income trading volumes. Fed and Treasury at Odds
• Negative Sentiment: Regulatory litigation: The Hyperliquid Policy Center filed an amicus brief urging dismissal of CME’s lawsuit against the CFTC. The development adds uncertainty to CME’s regulatory position and could weigh on sentiment surrounding its digital-asset and derivatives initiatives. Hyperliquid Policy Center Files Amicus Brief Urging Dismissal of CME’s Suit Against CFTC

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Barclays cut their price target on CME Group from $316.00 to $270.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 9th. UBS Group dropped their price objective on CME Group from $310.00 to $260.00 and set a "buy" rating for the company in a report on Monday, July 6th. Wall Street Zen upgraded shares of CME Group from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 29th. Keefe, Bruyette & Woods raised shares of CME Group from a "market perform" rating to an "outperform" rating and set a $305.00 target price on the stock in a research note on Thursday, June 18th. Finally, Morgan Stanley lifted their price target on shares of CME Group from $324.00 to $330.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, CME Group currently has a consensus rating of "Hold" and a consensus price target of $289.75.

CME Group Profile

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for a broad range of financial and commodity products. Its exchange platforms enable participants to manage risk, discover prices and gain exposure to asset classes including interest rates, equity indexes, foreign exchange, energy, metals, agricultural commodities and digital assets.

The company's principal marketplaces include CME, CBOT, NYMEX and COMEX. Products are offered through futures and options contracts, with electronic trading available through CME Globex as well as exchange-based and privately negotiated transactions.

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.